Nootropil Adverse Reactions

Clinical Studies: Double-blind placebo-controlled clinical or pharmacoclinical trials, of which quantified safety data are available (extracted from the UCB Documentation Data Bank on June 1997), included more than 3000 subjects receiving NOOTROPIL, regardless of indication, dosage form, daily dosage or population characteristics.
Adverse reactions are ranked under headings of frequency using the following convention: Very common ≥1/10, Common ≥1/100 to <1/10, Uncommon ≥1/1000 to <1/100, Rare ≥1/10000 to <1/1000, Very rare <1/10000, Not known (cannot be estimated from the available data).
Blood and lymphatic system disorders: Not known: haemorrhagic disorder.
Immune system disorders: Not known: anaphylactoid reaction, hypersensitivity.
Psychiatric disorders: Common: nervousness.
Uncommon: depression.
Not known: agitation, anxiety, confusion, hallucination.
Nervous system disorders: Common: hyperkinesia.
Uncommon: somnolence.
Not known: ataxia, balance disorder, epilepsy aggravated, headache, insomnia.
Ear and labyrinth disorders: Not known: vertigo.
Vascular disorders: Rare: thrombophlebitis (only for injectable form), hypotension (only for injectable form).
Gastrointestinal disorders: Not known: abdominal pain, abdominal pain upper, diarrhoea, nausea, vomiting.
Skin and subcutaneous tissue disorders: Not known: angioneurotic oedema, dermatitis, pruritus, urticaria.
General disorders and administration site conditions: Uncommon: asthenia.
Rare: pyrexia (only for injectable form), injection site pain (only for injectable form).
Investigations: Common: weight increased.